News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
162,363 Results
Type
Article (7667)
Company Profile (112)
Press Release (154584)
Section
Business (57314)
Career Advice (253)
Deals (9915)
Drug Delivery (12)
Drug Development (22352)
Employer Resources (22)
FDA (4120)
Job Trends (4528)
News (91699)
Policy (6515)
Tag
Academia (591)
Alliances (8644)
Alzheimer's disease (362)
Approvals (4121)
Artificial intelligence (25)
Bankruptcy (48)
Best Places to Work (3694)
Biotechnology (74)
Breast cancer (40)
Cancer (293)
Career advice (225)
Cell therapy (54)
Clinical research (18789)
Collaboration (64)
Compensation (25)
COVID-19 (634)
Data (369)
Diabetes (37)
Diagnostics (1603)
Earnings (38648)
Employer resources (21)
Events (24620)
Executive appointments (28)
FDA (4231)
Featured Employer (32)
Funding (60)
Gene therapy (36)
GLP-1 (157)
Government (995)
Healthcare (5363)
Infectious disease (651)
Inflammatory bowel disease (22)
Interviews (26)
IPO (5960)
Job creations (999)
Job search strategy (211)
Layoffs (102)
Legal (1115)
Lung cancer (58)
Lymphoma (21)
Manufacturing (37)
Medical device (3466)
Medtech (3467)
Mergers & acquisitions (4013)
Metabolic disorders (86)
Neuroscience (429)
NextGen Class of 2024 (1609)
Non-profit (1089)
Northern California (400)
Obesity (52)
Opinion (30)
People (7370)
Pharmaceutical (26)
Phase I (4801)
Phase II (8196)
Phase III (7207)
Pipeline (196)
Postmarket research (740)
Preclinical (1485)
Radiopharmaceuticals (37)
Rare diseases (58)
Real estate (1245)
Regulatory (4710)
Research institute (552)
Resumes & cover letters (25)
Southern California (339)
Startups (653)
United States (3570)
Vaccines (131)
Weight loss (31)
Date
Today (119)
Last 7 days (434)
Last 30 days (1003)
Last 365 days (10446)
2024 (9271)
2023 (11610)
2022 (14906)
2021 (15943)
2020 (14822)
2019 (12473)
2018 (9381)
2017 (8561)
2016 (7839)
2015 (9224)
2014 (6213)
2013 (4298)
2012 (4974)
2011 (5418)
2010 (4452)
Location
Africa (156)
Asia (9556)
Australia (1685)
California (859)
Canada (308)
China (56)
Colorado (30)
Connecticut (34)
Delaware (36)
Europe (23135)
Florida (119)
Georgia (34)
Illinois (82)
Indiana (56)
Maryland (146)
Massachusetts (664)
Michigan (36)
Minnesota (88)
New Hampshire (25)
New Jersey (360)
New York (255)
North Carolina (208)
Northern California (400)
Ohio (33)
Pennsylvania (212)
South America (291)
Southern California (339)
Texas (107)
Utah (28)
Washington State (124)
162,363 Results for "40".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
āshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue Disorders
āshibio exited stealth mode today with $40 million in seed and Series A financing.
June 20, 2024
·
6 min read
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Femasys, Inc. announces it will be participating at the European Society of Human Reproduction and Embryology’s (ESHRE) 40th Annual Meeting in Amsterdam on July 7-10.
June 27, 2024
·
4 min read
Press Releases
Inmagene to Host Virtual KOL Event on the Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata
October 9, 2024
·
6 min read
BioMidwest
Centene to Present at Bernstein 40th Annual SDC Conference 2024
Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives, announced it will present at the Bernstein 40th Annual Strategic Decisions Conference 2024.
May 27, 2024
·
1 min read
Layoffs
Shattuck Labs to Lay Off 40% of Workforce
As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.
October 1, 2024
·
2 min read
·
Angela Gabriel
BioMidwest
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.
May 16, 2024
·
3 min read
Pharm Country
Avantor® to Participate in Bernstein’s 40th Annual Strategic Decisions Conference
Avantor, Inc. announced that Michael Stubblefield , President and CEO, will be participating in a fireside chat at Bernstein’s 40th Annual Strategic Decisions Conference in New York.
May 21, 2024
·
1 min read
Dr. Reddy’s Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
Dr. Reddy’s Laboratories Ltd. today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA).
May 3, 2024
·
3 min read
Pharm Country
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
Amneal Pharmaceuticals, Inc. announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company’s total number of commercial injectable products available for the U.S. institutional market to over 40.
June 5, 2024
·
7 min read
Deals
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction– Transaction aligns with Coherus’ strategic focus on oncology –
Coherus BioSciences, Inc today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million.
June 27, 2024
·
4 min read
1 of 16,237
Next
